192 related articles for article (PubMed ID: 37660037)
1. Pivmecillinam with Amoxicillin/Clavulanic acid as step down oral therapy in febrile Urinary Tract Infections caused by ESBL-producing Enterobacterales (PACUTI).
Tverring J; Månsson E; Andrews V; Ljungquist O
Trials; 2023 Sep; 24(1):568. PubMed ID: 37660037
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of switching from intravenous to oral antibiotics (amoxicillin-clavulanic acid) versus a full course of intravenous antibiotics in neonates with probable bacterial infection (RAIN): a multicentre, randomised, open-label, non-inferiority trial.
Keij FM; Kornelisse RF; Hartwig NG; van der Sluijs-Bens J; van Beek RHT; van Driel A; van Rooij LGM; van Dalen-Vink I; Driessen GJA; Kenter S; von Lindern JS; Eijkemans M; Stam-Stigter GM; Qi H; van den Berg MM; Baartmans MGA; van der Meer-Kappelle LH; Meijssen CB; Norbruis OF; Heidema J; van Rossem MC; den Butter PCP; Allegaert K; Reiss IKM; Tramper-Stranders GA
Lancet Child Adolesc Health; 2022 Nov; 6(11):799-809. PubMed ID: 36088952
[TBL] [Abstract][Full Text] [Related]
3. Methenamine hippurate compared with antibiotic prophylaxis to prevent recurrent urinary tract infections in women: the ALTAR non-inferiority RCT.
Harding C; Chadwick T; Homer T; Lecouturier J; Mossop H; Carnell S; King W; Abouhajar A; Vale L; Watson G; Forbes R; Currer S; Pickard R; Eardley I; Pearce I; Thiruchelvam N; Guerrero K; Walton K; Hussain Z; Lazarowicz H; Ali A
Health Technol Assess; 2022 May; 26(23):1-172. PubMed ID: 35535708
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of gram-negative urinary tract infections caused by extended spectrum beta lactamases: pivmecillinam as a treatment option within South Dublin, Ireland.
O'Kelly F; Kavanagh S; Manecksha R; Thornhill J; Fennell JP
BMC Infect Dis; 2016 Nov; 16(1):620. PubMed ID: 27806687
[TBL] [Abstract][Full Text] [Related]
5. Ceftibuten plus amoxicillin-clavulanic acid for oral treatment of urinary tract infections with ESBL producing E. coli and K. pneumoniae: a retrospective observational case-series.
Cohen Stuart J; Leverstein-Van Hall M; Kortmann W; Verlind J; Mulder F; Scharringa J; Fluit A; Ekkelenkamp M
Eur J Clin Microbiol Infect Dis; 2018 Oct; 37(10):2021-2025. PubMed ID: 30117050
[TBL] [Abstract][Full Text] [Related]
6. Oral fosfomycin versus ciprofloxacin in women with E.coli febrile urinary tract infection, a double-blind placebo-controlled randomized controlled non-inferiority trial (FORECAST).
Ten Doesschate T; van Mens SP; van Nieuwkoop C; Geerlings SE; Hoepelman AIM; Bonten MJM
BMC Infect Dis; 2018 Dec; 18(1):626. PubMed ID: 30518334
[TBL] [Abstract][Full Text] [Related]
7. Clinical and bacteriological effects of pivmecillinam for ESBL-producing Escherichia coli or Klebsiella pneumoniae in urinary tract infections.
Jansåker F; Frimodt-Møller N; Sjögren I; Dahl Knudsen J
J Antimicrob Chemother; 2014 Mar; 69(3):769-72. PubMed ID: 24107388
[TBL] [Abstract][Full Text] [Related]
8. Breaking Antimicrobial Resistance: High-Dose Amoxicillin with Clavulanic Acid for Urinary Tract Infections Due to Extended-Spectrum Beta-Lactamase (ESBL)-Producing Klebsiella pneumoniae.
Wilkowski P; Hryniewiecka E; Jasińska K; Pączek L; Ciszek M
Ann Transplant; 2023 May; 28():e939258. PubMed ID: 37190675
[TBL] [Abstract][Full Text] [Related]
9. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.
Zhanel GG; Pozdirca M; Golden AR; Lawrence CK; Zelenitsky S; Berry L; Schweizer F; Bay D; Adam H; Zhanel MA; Lagacé-Wiens P; Walkty A; Irfan N; Naber K; Lynch JP; Karlowsky JA
Drugs; 2022 Apr; 82(5):533-557. PubMed ID: 35294769
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of pivmecillinam for treatment of lower urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
Titelman E; Iversen A; Kalin M; Giske CG
Microb Drug Resist; 2012 Apr; 18(2):189-92. PubMed ID: 22204597
[TBL] [Abstract][Full Text] [Related]
11. Effective Oral Combination Treatment for Extended-Spectrum Beta-Lactamase-Producing
Al-Tamimi M; Abu-Raideh J; Albalawi H; Shalabi M; Saleh S
Microb Drug Resist; 2019 Oct; 25(8):1132-1141. PubMed ID: 31107146
[No Abstract] [Full Text] [Related]
12. The efficacy of pivmecillinam in oral step-down treatment in hospitalised patients with E. coli bacteremic urinary tract infection; a single-arm, uncontrolled treatment study.
Hansen BÅ; Grude N; Lindbæk M; Stenstad T
BMC Infect Dis; 2022 May; 22(1):478. PubMed ID: 35590284
[TBL] [Abstract][Full Text] [Related]
13. A comparative trial of pivmecillinam/pivampicillin and amoxycillin/clavulanate in the therapy of urinary tract infection in a general practice population.
O'Dowd TC; Ribeiro CD; Smail JE; Menday AP; Howells CH
Curr Med Res Opin; 1984; 9(5):310-5. PubMed ID: 6397334
[TBL] [Abstract][Full Text] [Related]
14. Synergistic and bactericidal activities of mecillinam, amoxicillin and clavulanic acid combinations against extended-spectrum β-lactamase (ESBL)-producing Escherichia coli in 24-h time-kill experiments.
Skarp KP; Shams A; Montelin H; Lagerbäck P; Tängdén T
Int J Antimicrob Agents; 2019 Jan; 53(1):74-79. PubMed ID: 30236958
[TBL] [Abstract][Full Text] [Related]
15. Clavulanate combinations with mecillinam, cefixime or cefpodoxime against ESBL-producing Enterobacterales frequently associated with blaOXA-1 in a paediatric population with febrile urinary tract infections.
Birgy A; Madhi F; Jung C; Levy C; Cointe A; Bidet P; Hobson CA; Bechet S; Sobral E; Vuthien H; Ferroni A; Aberrane S; Cuzon G; Beraud L; Gajdos V; Launay E; Pinquier D; Haas H; Desmarest M; Dommergues MA; Cohen R; Bonacorsi S;
J Antimicrob Chemother; 2021 Oct; 76(11):2839-2846. PubMed ID: 34453533
[TBL] [Abstract][Full Text] [Related]
16. Clinical and bacteriological efficacy of pivmecillinam treatment for uncomplicated urinary tract infections caused by ESBL-producing Escherichia coli: a prospective, multicentre, observational cohort study.
Bollestad M; Grude N; Solhaug S; Raffelsberger N; Handal N; Nilsen HS; Romstad MR; Emmert A; Tveten Y; Søraas A; Jenum PA; Jenum S; Møller-Stray J; Weme ET; Lindbaek M; Simonsen GS;
J Antimicrob Chemother; 2018 Sep; 73(9):2503-2509. PubMed ID: 29982514
[TBL] [Abstract][Full Text] [Related]
17. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.
Bader MS; Loeb M; Leto D; Brooks AA
Postgrad Med; 2020 Apr; 132(3):234-250. PubMed ID: 31608743
[TBL] [Abstract][Full Text] [Related]
18. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections.
Veve MP; Wagner JL; Kenney RM; Grunwald JL; Davis SL
Int J Antimicrob Agents; 2016 Jul; 48(1):56-60. PubMed ID: 27234673
[TBL] [Abstract][Full Text] [Related]
19. Emerging clinical role of pivmecillinam in the treatment of urinary tract infections caused by Extended Spectrum βeta-lactamase (ESBL) producing Enterobacteriaceae.
Raja NS
Int J Clin Pract; 2019 Sep; 73(9):1-5. PubMed ID: 31243859
[TBL] [Abstract][Full Text] [Related]
20. Ibuprofen versus pivmecillinam for uncomplicated urinary tract infection in women-A double-blind, randomized non-inferiority trial.
Vik I; Bollestad M; Grude N; Bærheim A; Damsgaard E; Neumark T; Bjerrum L; Cordoba G; Olsen IC; Lindbæk M
PLoS Med; 2018 May; 15(5):e1002569. PubMed ID: 29763434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
